Reuters logo
9 months ago
BRIEF-Biogen and Ionis Pharmaceuticals announce SPINRAZA meets primary endpoint at interim analysis of phase 3 cherish study
November 7, 2016 / 1:53 PM / 9 months ago

BRIEF-Biogen and Ionis Pharmaceuticals announce SPINRAZA meets primary endpoint at interim analysis of phase 3 cherish study

Nov 7 (Reuters) - Ionis Pharmaceuticals Inc

* Biogen and Ionis Pharmaceuticals announce SPINRAZA (nusinersen) meets primary endpoint at interim analysis of phase 3 cherish study in later-onset spinal muscular atrophy

* Spinraza demonstrated a favorable safety profile in study

* Biogen is preparing for potential launch of SPINRAZA in U.S. possibly as early as end of 2016 or q1 of 2017

* Ionis pharmaceuticals says analysis found children receiving SPINRAZA experienced highly statistically significant improvement in motor function versus those who didn't receive treatment Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below